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Abstract In order to study estrogen-driven microenviron-
ment associated with type 1 endometrial carcinoma, we
evaluated estrogen receptors (ERs), aromatase, and cycloox-
ygenase II (COX2) molecular and immunohistochemical
profiles with correlation to clinicopathological features. We
investigated aromatase, ERα, ERβ, and COX2 expression at
the mRNA and protein levels using quantitative real-time
PCR and immunohistochemical method in 51 endometrial
carcinomas and 16 normal endometria. All the studied tu-
mors, as well as normal endometria, expressed ERα, ERβ,
and COX2 mRNAs. Five endometrial carcinoma tissues and
one normal endometrium showed no aromatase mRNA ex-
pression. The majority of tumors expressed ERα (82 %),
aromatase (80 %), and COX2 (88 %) proteins. Forty-one
percent of the studied tumors were ERβ-negative. ERα and
ERβ showed significantly decreased mRNA and protein ex-
pression levels in endometrial carcinoma as compared to nor-
mal endometrium. An opposite trend was shown for COX2 and
aromatase proteins. ERα expression correlated positively with
COX2 expression at both mRNA and protein levels (P<0.005,
r=0.398; P<0.0005, r=0.510, respectively). There was also a
positive correlation between COX2 and aromatase expression
in cancer tissue (P<0.002, r=0.433 for transcriptional level;
P<0.0005, r=0.614 for protein level). We observed positive
correlations between ERβ and ERα, as well as between ERβ
and COX2 at the transcriptional level only (P<0.0005,
r=0.644; P<0.002, r=0.444, respectively). Negative correla-
tions were found between pT category of primary tumor and
levels of ERα and ERβ transcripts (P<0.02, r=−0.332;
P<0.02, r=−0.348, respectively). A negative association be-
tween ERβ and the International Federation of Gynecology
and Obstetrics (FIGO) staging was also found. The growth of
EC1 with the presence of ERα and overexpression of aroma-
tase and COX2 is dependent on estrogens. We believe that
ERβ may be considered as a potential marker in the progres-
sion of disease in endometrial cancer patients.
Keywords ERs (ERα, ERβ) . Aromatase . COX2 . Type 1
endometrial cancer
Introduction
Endometrial adenocarcinoma is the most common gyneco-
logic malignancy in women worldwide. The precise molec-
ular mechanism underlying endometrial carcinoma is poorly
understood; however, it is known that the development of
endometrial carcinoma (EC) occurs as a result of genetic,
metabolic, and hormonal changes. A dualistic model of
endometrial cancer was proposed based on histological and
molecular pathology observations, i.e., type 1—estrogen-
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dependent adenocarcinoma with endometrioid morphology
(EC1), and type 2—non-estrogen-dependent adenocarcino-
ma (EC2) [1, 2].
The risk of EC1 is postulated to be linked with prolonged
estrogen exposure and action, especially that unopposed by
progestogens [3–5]. Unbalanced estrogen excess can lead to
an increase in the proliferation rate of endometrial cells with
an increasing frequency of coding errors and somatic muta-
tion appearance [6].
The biological effect of estradiol in the uterus is mediated
through two estrogen receptors: estrogen receptor (ER) α
and ERβ. The distinct role of these two receptors in the
uterus was evaluated using ERα (αERKO) and ERβ
(βERKO) knockout female mice study. ERα plays an im-
portant role in the differentiation and proliferation of epithe-
lial cells, whereas the role of ERβ was proposed to act as
ERα modulator exerting an antiproliferative function in the
uterus [7]. The most important question is whether the same
mechanisms of ER action observed in the uterus of knockout
mice might exist in human healthy and/or malignant endo-
metrial tissue.
In normal premenopausal endometrium, the ER expres-
sion and distribution change during the cycle. ERα and ERβ
are mainly co-expressed in the glandular epithelial cells with
similar cyclic changes in the uterus, with a markedly higher
ERα expression compared to ERβ during proliferative as well
as secretory phases. ERs were also shown to be expressed in
stromal cells, with predominance of ERα and a weaker ex-
pression of ERβ in the proliferative phase and ERβ absence in
the secretory phase [7].
The number of studies on the significance of ER-dependent
signaling in endometrial tumor cells is still limited. Addition-
ally, there are certain conflicting data on the usefulness of the
estrogen receptor status as an independent prognostic factor in
endometrial cancer patients.
However, it has been shown that endometrial cancer cells
are estrogen-responsive and are controlled by endogenous
ERs and local estrogen biosynthesis [8]. Recent studies on
estrogen-dependent tumors such as breast and endometrial
cancers revealed the significance of in situ estrogen biosyn-
thesis and metabolism in the biology of these tumors. The
main source of intratissular estrogens in estrogen-dependent
EC1 tumors is the bioconversion of androgen to estrogen in
the stromal cells by the key enzyme involved in local estro-
gen production, i.e., aromatase [9]. Segawa et al. [10] re-
vealed the role of aromatase in tumor progression, demon-
strating a significant correlation between aromatase expres-
sion in stromal cells and poor prognosis in women suffering
from endometrial cancer. The main secretory factor inducing
aromatase expression in the surrounding stromal cells in
breast tumor was found to be prostaglandin E2 (PGE2) [11,
12]. A similar mechanism of aromatase induction seems to
occur in endometrial cancer. In EC1, similarly to breast
cancer, the expression level of aromatase correlates with
cyclooxygenase II (COX2), the enzyme responsible for
PGE2 synthesis. In addition, estrogens which act through
both estrogen receptors and are synthesized by aromatase in
postmenopausal women could increase COX2 expression
level in this way.
The aim of our study was to investigate ERs, aromatase,
and COX2 expression in type 1 endometrial cancer and nor-
mal endometrium with the molecular and clinical correlations.
Materials and methods
Patients and samples
Tissue samples were obtained from 51 postmenopausal
women who underwent total abdominal hysterectomy be-
cause of endometrial carcinoma. Standard histopathological
parameters were determined by two independent patholo-
gists. In each case, endometrial cancer risk factors such as
age, the presence of hypertension, obesity, and type 2 diabe-
tes were evaluated. The age of patients ranged from 48 to
80 years (mean 64 years). Tumor stage, age range, and body
mass index (BMI) of endometrial cancer patients are
presented in Table 1. Histologically, normal endometrium
samples of middle to late proliferative phase of menstrual
cycle were obtained during hysterectomies due to uterine
leiomyomas from 10 (for immunohistochemical (IHC) study)
and 16 (for molecular analysis) premenopausal women (age
range 35–54 years). The specimens collected for molecular
analysis were frozen in liquid nitrogen and kept at −80 °C
until molecular studies were performed. For IHC study, tissue
samples were fixed in 10 % buffered formaldehyde solution




Parameter No. of cases
Tumor stage and grade
Stage IA grade 1 9
Stage IA grade 2 10
Stage IA grade 3 1
Stage IB grade 2 10
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for 48 h and then embedded in paraffin blocks at 56 °C
according to standard procedures. Tumor samples were cut
into 5-μm-thick sections and stained with hematoxylin–eosin.
The protocol of this study was approved by the local
ethical committee of the Medical University of Bialystok,
Poland.
RNA extraction and cDNA synthesis
Total RNA was extracted from EC and endometrial control
tissues according to the Chomczynski and Sacchi method
with a minor modification [13]. RNA integrity was verified
by electrophoresis in 1.5 % (w/v) agarose gel and staining
with ethidium bromide, and by amplification of housekeep-
ing gene, 18s rRNA. RNAwas quantified spectrophotomet-
rically at 260 nm. One microgram of total RNAwas used to
prepare cDNA. cDNA synthesis was performed in 50 mM
Tris–HCl (pH 8.3), 75 mMKCl, 3 mMMgCl2, 10 mM DTT,
1 mM dNTP mix (Promega), 2.5 μM random hexamers,
20 U RNasin Ribonulease Inhibitor (Promega), and 100 U
MMLV Reverse Transcriptase (Promega) in a final volume
of 40 μl using an MJ Research Thermal Cycler (Model PTC-
200, Watertown, Massachusetts, USA). For reverse tran-
scription, the mixtures were incubated at 42 °C for 60 min
and then heated at 95 °C for 5 min and finally rapidly cooled
at 4 °C. Negative control samples were generated by omit-
ting the enzymes and RNA template in the reverse transcrip-
tion reaction.
Quantitative real-time PCR
In order to determine the amounts of ERα, ERβ, aromatase,
and COX2 expression levels, standard curves for each gene
separately were constructed with serially diluted PCR prod-
ucts. PCR products were obtained by amplification of cDNA
from Ischikawa cells using specific primers as follows: 5′
TGCTTCAGGCTACCATTATGGAGTCTG3′ and 5′GTCA
GGGACAAGGCCAGGCTG3′ for ERα; 5′TTTAAAAGA
AGCATTCAAGGACATAATG3′ and 5′CGGTGAAGGGC
GCACTG3′ for ERβ; 5′GCCACTGAGTTGATTTTAGC3′
and 5′CCAAATGGCTGAAAGTACC3′ for aromatase; 5′CT
CAAACATGATGTTTGCATTC3′ and 5′CAGGGACTTGAG
GAGGGTTAGATC3′ for COX2; and 5′CGTCTGCCCTATC
AACTTTCG3′ and 5′CGCGGTCCTATTCCATTATTC3′ for
18s rRNA. PCRwas carried out in a final volume of 20μl using
10 pmol of each of the primers, 40μMof each of dNTPs, 1 U
HotStarTaq polymerase (Qiagen GmbH, Hilden, Germany),
2 μl 10× PCR buffer, and 2 μl cDNA. PCR was carried out
under the following conditions: 15 min polymerase activation
at 95 °C, 1 min denaturation at 94 °C, 1 min annealing at
65 °C, and 1 min extension at 72 °C for 40 cycles, with an
additional 5 min of extension at 72 °C for the last cycle.
Amplified products were separated on a 2 % (w/v) agarose
gel, extracted, and purified from agarose slices using DNA
Gel Extraction Kit (Millipore, USA), quantified by the use of
One Dscan/Zero Dscan software (Scanalytics Inc., USA) and
then serially diluted in sterile water.
We used Assays-on Demand Gene Expression Assays
(Applied Biosystems) to determine the mRNA level of the
studied genes. All the quantitative real-time (Q-RT) PCR
reactions were performed using ABI Prism 7500 Sequence
Detection System (Applied Biosystems, USA). For each
PCR run, a reaction mix was prepared with 10 μl 2× TaqMan
Gene Expression PCR Master Mix (Applied Biosystems),
1 μl 20× Assays-on Demand Gene Expression Assay Mix
(Applied Biosystems), 2 μl cDNA, and sterile water to the
final volume of 20 μl. To evaluate the amounts of the
studied transcripts, all the results obtained in attogram or
femtogram according to standard curves were converted to
attomole or femtomole of each transcript and then normalized
by the level of 18s rRNA. The relative quantification was
given by the ratio between the mean value of the target gene
and the mean value of the reference gene (18s rRNA) for each
sample.
Immunohistochemistry
For immunohistochemical studies, we selected two represen-
tative sections from each case.
Five biological markers were investigated using IHC
study: ERα, ERβ, COX2, aromatase, and Ki-67. ERα was
detected with a mouse monoclonal antibody (Ab) F-10
(Santa Cruz Biotechnology, USA) at a dilution of 1:200.
ERβ was detected with a monoclonal Ab EMR02 (NCL-
ER-beta, Novocastra) at a dilution of 1:100. COX2 was
assessed using monoclonal Ab (NCL-COX2, Novocastra)
at a dilution of 1:200. Ki-67 was assessed using the mono-
clonal mouse Ab MIB-1 (Dako, Denmark) at a dilution of
1:100. Aromatase expression was assessed using a rabbit
polyclonal Ab R-10-2 against cytochrome P450 aromatase
at a dilution of 1:800 (a generous gift from Dr. Yoshio
Osawa, Hauptman-Woodward Medical Research Institute,
Buffalo, NY, USA).
The sections were deparaffinized in xylenes and hydrated
through graded alcohols. Antigen unmasking was performed
using heat treatment in a microwave oven at 750W for 6 min
in a container with 10 mM sodium citrate buffer at pH 6.0.
The sections were allowed to cool in the buffer at room
temperature for 30 min and were rinsed in deionized H20
three times for 2 min each. The endogenous peroxidase
activity was blocked with 1 % hydrogen peroxide for
20 min. After rinsing in PBS, the sections were incubated
for 1 h with a proper 1.5 % normal blocking serum in PBS.
The blocking reagent was removed, and then the sections
were incubated with MIB-1 antibody for 1 h at room tem-
perature or with ERα, ERβ, COX2, and aromatase antibody
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at 4 °C overnight using staining chamber (The Binding Site,
UK). Primary antibodies were diluted in PBS with 1.5 %
normal blocking serum.
The studies for ERβ, COX2, and aromatase were performed
with EnVision System (Dako, Denmark); for ERα, with avi-
din–biotin-peroxidase complex (ABC Staining System, Santa
Cruz, USA); and for Ki-67, with streptavidin–biotin-peroxi-
dase complex (LSAB Kit, Dako, Denmark) to reveal
Ab–antigen reactions. Staining was routinely developed using
3,3′-diaminobenzidine as a chromogen (Dako, Denmark). The
sections were counterstained with hematoxylin.
Immunoreactivities were scored in light microscopy in ten
different fields under magnification of ×200, and the mean
percentage of tumor cells which showed positive staining was
assessed. In discriminating protein-positive from -negative tu-
mors, the cutoff was 10 % malignant cells that expressed the
investigated marker from all the cancer cells of the microscopic
slide. The expression of the studied markers (ERs, COX2, Ki-
67) was graded in four-tiered system: 0 (defined as negative
cases) less than 10 % positive cells (thus, this was in reality a
very weak positive result); 1+ with immunoreactivity ranging
from 10 to 50 % of positive cancer cells (moderately positive);
2+ with over 50 % of positive cells; and 3+ over 50 % of
positive cells with a strong reaction. The expression of aroma-
tase was graded in five-tiered system: 0 (defined as negative
cases) less than 10 % positive cells; 1+ with immunoreactivity
ranging from 10 to 50 % of positive cancer cells (moderately
positive); 2+ with over 50 % of positive cells (positive reac-
tion); 3+ less than 50 % of positive cells with a strong reaction;
and 4+ over 50 % of positive cells with a strong reaction.
Statistical analysis
Mean values ± standard deviation (SD) and median were
calculated. The Student t test was used to compare normally
distributed continuous variables and Mann–Whitney for ab-
normally distributed ones. The Spearman’s and Pearson’s
correlation coefficients were estimated. Linear regression
analysis was also used. The analysis was done using statistical
software package SPSS, accepting P<0.05 as significant.
Results
Expression profile of ERα, ERβ, aromatase, and COX2
in EC and normal endometrium
To evaluate the levels of ERα, ERβ, aromatase, and COX2
mRNA expression, Q-RT-PCR with manually prepared curves
was used. All results obtained in femtogram for ERα and
COX2 or attogram for ERβ and aromatase were converted to
femtomole or attomole of transcript per microgram of total
RNA and then normalized by the level of 18s rRNA. All the
studied tumors as well as normal endometria expressed ERα,
ERβ, and COX2 mRNAs. Five EC tissues and one normal
endometrium showed no aromatase mRNA expression. The
studied cancerous samples showed the highest values of ERα
transcript at femtomolar levels ranging from 0.43 to 286.98with
one cancerous tissue presenting elevated ERα mRNA level:
1,776.04 (mean 85.92±SD 258.58) comparing to normal endo-
metria ranging from 38.7 to 681.4 (mean 253.99±SD 172.75).
ERβ and aromatase were expressed at the lowest transcriptional
attomolar level (0.0026 to 5.69, mean 0.48±SD 1.02 for ERβ in
cancerous tissues; 0.36 to 2.94, mean 0.88±SD 0.81 for ERβ in
control tissues; 0.0002 to 0.29, mean 0.02±SD 0.06 for aroma-
tase in cancerous tissues; and 0.0005 to 0.24, mean 0.03±SD
0.02 for aromatase in normal endometria) (Table 2, Fig. 1).
Antigen expressions were analyzed by immunohisto-
chemistry in all the human endometrial tumors and normal
endometria mentioned above; the results are presented in
Tables 2 and 3. ERα (Fig. 2a) and Ki-67 (Fig. 2d) were
detected in the nuclei, whereas ERβ (Fig. 2b) was found in
the cytoplasm of cancer and normal endometrial cells. We
observed COX2 expression mainly in the cytoplasm of nor-
mal endometrial and cancer cells, and only a few inflamma-
tory cells showed a positive COX2 expression (Figs. 2e, f
and 3a, b). Aromatase expression was detected mainly in the
cytoplasm of cancer endometrial cells, and only weak im-
munostaining was found in part of normal endometria as
well as in stromal cells (Figs. 2c and 3c, d).
In the present study, the analyzed EC tissues showed a
much larger amount of both ERα and ERβ mRNAs than
normal endometrial tissues (Fig. 1, Table 2). IHC study
confirmed greater expression of ERα and ERβ proteins in
normal endometrium compared with EC, yet with no signif-
icant difference (Table 2).
Aromatase mRNA levels in the normal and cancerous
endometrial samples were extremely low.We observed small
differences in aromatase mRNA expression levels between
tumor and normal tissues with slightly elevated mRNA level
in normal tissues (Fig. 1, Table 2). An opposite trend was
found for aromatase at the protein level which was signifi-
cantly higher in EC than in the control tissues (Table 2).
Interestingly, 50 % of studied normal endometria showed no
aromatase expression, and 50% of those tissues showed only
weak (1+) aromatase immunostaining (Table 3, aromatase).
About 60 % of the studied cancerous endometria expressed
aromatase at a high level (2+, 3+, 4+) (Table 3, aromatase).
The expression of COX2was significantly elevated in EC in
comparison to the control tissue (Tables 2 and 3, COX2; Fig. 1).
Correlations between ERα, ERβ, aromatase,
and COX2 in EC
ERα expression correlated positively with COX2 expression
at both mRNA and protein levels (P<0.005, r=0.398;
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P<0.0005, r=0.510, respectively). There was also a statisti-
cally significant positive correlation between COX2 and
aromatase expression in cancer tissue (P<0.002, r=0.433
for the transcriptional level; P<0.0005, r=0.614 for the pro-
tein level). Positive correlations were also observed between
ERβ and ERα as well as ERβ and COX2 at the transcriptional
level only (P<0.0005, r=0.644; P<0.002, r=0.444, respec-
tively). A negative correlation was found between ERα
mRNA expression and Ki-67 status (P<0.04, r=−0.299).
Correlations of ERα, ERβ, aromatase, and COX2 expres-
sionwith selected clinical, pathological, andmetabolic features
Statistically negative correlations were found between
depth of myoinvasion—pT category (where T1A—tumor
limited to the endometrium or invades less than one half of
the myometrium; T1B—tumor invades one half or more of
the myometrium; T2—tumor invades stromal connective
tissue of the cervix but does not extend beyond the uterus;
and T3—tumor involves the uterine serosa, parametrium,
vagina, or adnexa) and levels of ERα and ERβ transcripts
(P<0.02, r=−0.332; P<0.02, r=−0.348, respectively). In-
terestingly, ERβ expression assessed by Q-RT-PCR was
negatively correlated with the International Federation of
Table 2 Comparison of mRNA levels and mean values of antigens expressions of ERs, aromatase and COX2 between studied endometrial cancers
(EC) and normal endometrium tissues (control) using Q-RT-PCR study and immunohistochemistry (IHC study)
Group Q-RT-PCR study IHC study
Number Mean SD P value Number Mean SD P value
ERα EC 48 85.92 258.58 0.0005 49 1.39 0.931 ns
Control 15 253.99 172.75 10 1.90 0.738
ERβ EC 48 0.48 1.02 0.0005 51 0.88 0.887 ns
Control 15 0.88 0.81 10 1.60 1.174
Aromatase EC 48 0.02 0.06 0.012 50 2.06 1.236 0.0005
Control 14 0.03 0.02 10 0.50 0.527
COX2 EC 48 9.78 19.58 ns 51 1.71 1.006 0.011
Control 15 6.33 7.16 10 0.80 0.789
Fig. 1 Comparative analysis of
ERα (a), ERβ (b), aromatase (c),
and COX2 (d) mRNA
expression levels in endometrial
cancer (EC) and normal
proliferative endometrium
(control). Statistically lower
expression level of ERα, ERβ,
and aromatase in cancerous
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Gynecology and Obstetrics (FIGO) stage (P=0.007, r=−0.385).
Additionally, linear regression analysis, with FIGO stage as
dependent variable, confirmed negative influence of ERβ
mRNA expression (B coefficient=−0.386) and also ERβ pro-
tein level (B coefficient=−0.411) on FIGOwith r square=0.247.
We also found that the expression of ERα at mRNA and
protein level was negatively associated with tumor differen-
tiation (G) (P<0.02, r=−0.337; P<0.05, r=−0.288, respec-
tively). Moreover, we observed weak statistically significant
differences in Ki-67 proliferation status and G (P<0.02,
r=0.321). We found no association between the expression
levels of the studied factors and the age of patients.
No correlations between hypertension, smoking, and dia-
betes and the expression level of the studied genes were
found. However, aromatase at the protein level was positively
associated with BMI (P<0.01, r=0.346).
Discussion
The incidence of estrogen-dependent type 1 endometrial can-
cer is the highest in postmenopausal women when the ovaries
have ceased producing estrogen. Despite its relatively good
prognosis when diagnosed in its early stages, more than 20 %
of patients die due to endometrial carcinoma [14, 15]. This
data may reflect, at least partly, the failure of currently avail-
able diagnostic tools in EC, especially in identifying prema-
lignant stages. There are still gaps in developing efficient
prognostic markers and individual treatment in EC.
Type 1 endometrial adenocarcinoma is accepted to be an
endocrine-related neoplasm and an established target of es-
trogen action. In order to study the estrogen-driven microen-
vironment associated with EC, we evaluated ERs, aromatase,
and COX2 status in endometrial cancer patients. Estrogen in
postmenopausal EC women originates from peripheral sites,
mainly from adipose tissue and in cancerous endometrium
from precursors of adrenal or ovarian origin via aromatase
pathway. However, the data on aromatase expression in both
normal and cancerous endometria seem rather unclear. There
are discrepancies in the results presented in the available
literature. The available studies show no aromatase mRNA
in nonmalignant tissue versus cancerous tissue [16] and no
significant differences between cancerous and adjacent nor-
mal endometrium [17–19], or demonstrate increased aroma-
tase activity in neoplastic endometrium [20]. Our present
study shows that the aromatase mRNA level was slightly
higher in normal tissue in comparison to cancerous endome-
trium. Interestingly, protein expression and distribution anal-
ysis revealed aromatase overexpression in cancer tissue. More
than 60 % of the studied EC showed strong cytoplasmic
immunoreactivity, whereas normal endometrium presented
very low (1+) or negative aromatase expression in glandular
epithelial and stromal cells. We showed no correlation be-
tween aromatase expression and clinicopathological EC char-
acteristics; however, aromatase at the protein level was posi-
tively associated with BMI. BMI is an unquestionable risk
factor of endometrial cancer [21, 22]. It is not surprising that
aromatase expression responsible for hyperestrogenic state in
Table 3 Percentage distribution of positive cells showing expression of studied proteins in endometrial cancerous tissues in comparison with normal
endometria according to immunoreactivity of ERα, ERβ, aromatase, and COX2
Group IHC staining Total
0 1+ 2+ 3+ 4+
ERα EC Number 9 18 16 6 49
% Within EC group 18.4 36.7 32.7 12.2 100.0
Endometrial control tissue Number 0 3 5 2 10
% Within control group 0.0 30.0 50.0 20.0 100.0
ERβ EC Number 21 17 11 2 51
% Within group 41.2 33.3 21.6 3.9 100.0
Endometrial control tissue Number 2 3 2 3 10
% Within group 20.0 30.0 20.0 30.0 100.0
Aromatase EC Number 5 14 11 13 7 50
% Within group 10.0 28.0 22.0 26.0 14.0 100.0
Endometrial control tissue Number 5 5 0 0 0 10
% Within group 50.0 50.0 0.0 0.0 0.0 100.0
COX2 EC Number 6 17 14 14 51
% Within group 11.8 33.3 27.5 27.5 100.0
Endometrial control tissue Number 4 4 2 0 10
% Within group 40.0 40.0 20.0 0.0 100.0
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postmenopausal women is associated with the excess of adi-
pose tissue as we have shown in the present study. However,
some studies, focused on the increased BMI and treatment
outcome in EC, revealed that elevated BMI is not an unfavor-
able prognosticator [23–25], in contrast with breast, ovary,
prostate, and colorectal malignancies. Recent findings from
the MRC ASTEC trial indicated that obesity related to
hyperestrogenic state is associated with an increased incidence
of the less aggressive type of endometrial cancer (type 1) and
thus predicts for a more favorable outcome after treatment [26].
The statistically positive correlation between aromatase
and COX2 shown in our study confirms that apart from
aromatase, COX2 seems to be another important player in
the hormonal loop implicated in estrogen production in EC.
We have shown that COX2 is expressed at a markedly higher
level in cancerous endometrium compared to normal endo-
metrium. Despite the evident differences between the mean
values of COX2 transcript levels in cancerous versus normal
endometrium, we observed no significant association. Inter-
estingly, at the protein level, COX2 was statistically signif-
icantly elevated in tumor as compared to normal endometri-
um controls. Moreover, all of the studied endometrial tumor
samples expressed COX2 in the cytoplasm of cancer as well
as inflammatory cells; however, 40 % of control tissues did
not show the COX2 expression. We observed a very high
immunoreactivity (2+ and 3+) in cancerous cells in 55 % of
the patients.
Recent studies, presenting proteomic approach, confirmed
that there exist several dysregulated and metabolic networks
in EC [27]. Indeed, the authors revealed the significant inter-
actions between some of the altered molecule families asso-
ciated with oxidative phosphorylation, mitochondrial dys-
function, and inflammatory process. Among the candidate
biomarkers associated with the early stages of tumorigenesis
process in EC, COX2 was found to correlate with NFkB-
regulated cytokines and their receptors and, indirectly, with
Fig. 2 a–f Immunohistochemical
detection of ERα, ERβ,
aromatase, Ki-67, and COX2 in
the human endometrial cancer.
a Strong nuclear immunostaining
of ERα in endometrial cancer
cells with most intense
immunoreactivity in the invasive
front of tumor. bMainly
cytoplasmic and only weak
perinuclear localization of
ERβ in cancerous cells. c Strong
cytoplasmic immunostaining
of aromatase in endometrial
cancer cells. d Nuclear
heterogeneous immunostaining
of Ki-67. e–f Strong cytoplasmic
immunostaining of COX2 in
cancerous cells with focal
perinuclear immunoreactivity.
Original magnification: a ×100.
b–e ×200. f ×400
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the protein from peroxiredoxin family (PRD3) involved in
supporting tumor maintenance in cancer cells [27]. The role
of estrogens and their receptors in this oxidative/inflammatory
network is still not clear. However, contrary to others [28], our
study reveals the correlation between ERα and COX2, at both
transcriptional and protein levels, whereas ERβ is associated
with COX2 only at the mRNA level, suggesting that there
might be a similar biological pathway in endometrial cancer
cells that could sustain steroid hormones and COX2-mediated
cellular activities. The divergent pattern of ERα and COX2
distributions in endometrial cancer do not exactly exclude the
positive correlation between these studied factors. It is possi-
ble that in the tumors possessing ERα, the ERα expression
level is positively correlated with COX2, despite the divergent
distribution of these transcripts/proteins in cancerous versus
control tissues. It is well accepted that estrogenic effect in
endocrine-dependent cancers, including endometrial cancer,
occurs predominantly through ERα; however, the role of ERβ
in endometrial carcinogenesis process or tumor phenotype
and biology still remains an open question. Our present study
is in accordance with the previous data showing higher ERs
expressed in noncancerous endometrium compared with en-
dometrial cancer [29]. However, Knapp et al. [30] showed
elevated ER protein level in endometrial cancer compared to a
healthy mucosa. The analysis of the early stage of endometrial
carcinoma (FIGO I stage only) and use of Western blot meth-
od for estimating protein level of ERswith different antibodies
may explain the discrepancy. Moreover, our present study
reveals that ERα is always expressed in normal endometrium,
while about 18 % of the studied ECs are ERα-negative. ERβ
is differently expressed in these two types of tissues. In con-
trast to ERα, ERβ is absent in 20 % of normal proliferative
endometrial tissues, and 41.2 % of the examined cancer
tissues are ERβ-negative.
It is believed that the imbalance in the ERα/ERβ expres-
sion could be a possible critical step in the progress
Fig. 3 a–d. Expression of
COX2 and aromatase in
endometrial cancer and adjacent
normal endometrium. a, b
Cytoplasmic localization of
COX2 immunostaining in
endometrial and cancer cells
with weak or strong expression,
respectively. c, d Strong
cytoplasmic immunoreactivity
of aromatase in endometrial
cancer, while only weak
immunostaining in part of
normal endometrium as well
as in stromal cells. Original
magnification: a ×100.
b–d ×200
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of estrogen-dependent tumorigenesis. Some authors pro-
posed that altered balance of ERα/ERβ toward decreasing
ERα/ERβ ratio due to significantly lower ERα expression
could lead to a perturbed effect on cell-cycle progression and
further increase the cell risk of transforming mutations [31,
32]. However, our data showed no statistically significant
differences in the ERα/ERβ ratio between normal and can-
cerous endometrium.
In the present study, we revealed mainly cytoplasmic and
only weak perinuclear localization of ERβ in cancerous
cells. This cytosolic existence of ERβ might indicate the
mechanism of ER action on tumor biology that is probably
different from the classical one. The presence of ERβ within
the mitochondria and therefore its action with mitochondrial
molecules or proteins might presumably influence the hor-
monal phenotype of EC1. Interestingly, we demonstrated a
negative association between ERβ and FIGO stage using
linear regression analysis. However, it should be noted that
the majority (66 %) of EC1, included in this study, was
diagnosed as FIGO I, grades 1–3. Our observation favors
the idea about the potential protective role of ERβ against
endometrial tumor progression.
It should be noted, that the estrogen effect can be mediat-
ed not only by genomic action through classical ERs but also
by the nongenomic pathway through membrane estrogen
receptor, i.e., G protein-coupled estrogen receptor (GPER).
Indeed, GPER together with ERα recently were found to be
expressed in epithelial and stromal cells of normal human
endometrium, especially in the proliferative phase [33].
Interestingly, loss of GPER in ERα-positive patients
suffering from endometrial cancer resulted in reduced 5-
year survival [34]. These data, together with our results, could
direct future studies to delineate the role of classical ERs and
membrane ER-dependent pathways in endometrial cancer
pathology.
In summary, when we compared EC1 versus noncancerous
endometrial tissue, we were able to show decreased mRNA
and protein expression of ERs in EC1. Aromatase and COX2
protein overexpression and distribution in EC1 provide estro-
gen source in these tumors. Altogether, estrogens produced
locally in EC1 (by the aromatase–COX2 loop) through ERα
may possibly enhance tumor growth. This statement should be
verified using in vitro studies. The role of ERβ in the
cancerous process in endometrial tissue is still not precisely
defined. However, our observations suggest that ERβ may
play an important role in the etiology and biology of EC1 and
may protect against the growth-promoting effects of the
estrogens.
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